Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 22

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 22
---
,249,340 ordinary shares represented by 12,349,956 ADSs issuable upon exercise of pre-funded warrants issued in the November 2024 Registered Direct Offering, at an exercise price of $0.0001 per ADS, of which 135,774,465 ordinary shares 
 represented by 9,051,631 ADSs were issued following the cashless exercise of such pre-funded warrants after September 30, 2024;                                                                                                                |

| • | 123,535,860 ordinary shares represented by 8,235,724 ADSs issuable upon exercise of warrants to be issued in the November 2024 Registered Direct Offering, at an exercise price of $0.5900 per ADS; |

| • | 235,018,170 ordinary shares represented by 15,667,878 ADSs issuable upon exercise of pre-funded warrants to be issued to the investors in this offering, at an exercise price of $0.0001 per ADS; |

| • | 750,000,000 ordinary shares represented by 50,000,000 ADSs issuable upon exercise of warrants to be issued to the investors in this offering, at an exercise price of $0.20 per ADS; and |

| • | 37,500,000 ordinary shares represented by 2,500,000 ADSs issuable upon exercise of warrants to be issued to the placement agent or its designees as compensation in connection with this offering, at an exercise price of $0.25 per ADS. |

S - 11 DILUTION If you invest in the ADSs or pre-funded warrants and accompanying warrants, your interest will be diluted immediately to the extent of the difference between the public offering price per ADS or pre-funded warrant and associated warrant and the as adjusted net tangible book value per ADS after this offering. The net tangible book value of our ADSs as of September 30, 2024 was $(4.7) million, or $(0.06) per ADS. Net tangible book value per ADS represents the amount of our total tangible assets less total liabilities divided by the total number of our ordinary shares outstanding as of September 30, 2024, multiplied by 15 (i.e., the number of ordinary shares underlying each ADS).

After giving effect on a pro forma basis to (A) the sale in the November 2024 Registered Direct Offering (i) 4,121,493 ADSs, representing 61,822,395 ordinary shares, and warrants to purchase up to